403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Fennec Pharmaceuticals Inc.
(MENAFN- Baystreet) 10:15 AM EST - Fennec Pharmaceuticals Inc.: Today announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK® (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. Fennec Pharmaceuticals Inc.
shares T are trading unchanged at $8.93.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment